News & Press Releases

Minneapolis Heart Institute Foundation® (MHIF) enrolled the first patient in the TRIVITA US pivotal study evaluating the TriNova™ transcatheter tricuspid valve replacement (TTVR) (from Minnesota‑based VDyne Inc.). This is an important milestone in efforts to advance treatment options for patients living with severe tricuspid regurgitation (TR), which involves a leaky tricuspid heart valve. 

Minneapolis Heart Institute Foundation enrolled the first patient in AngioInsight’s SMARTFLOW™ clinical study, marking a major milestone in the clinical evaluation of the investigational AngioAI+™ platform, an investigational software platform designed to assess coronary physiology from routine coronary angiographic images.

MHIF welcomes Parth Desai, MD, as the Frank J. and Eleanor Maslowski Charitable Trust CHIP-CTO Fellow, effective July 1, 2026.

Minneapolis Heart Institute Foundation physician researchers have performed the first case in Minnesota using the Medtronic Sphere-360™ pulsed field ablation (PFA) catheter as part of the Horizon 360 clinical trial, evaluating the investigational, next-generation technology designed to transform the treatment of paroxysmal atrial fibrillation (AFib).

On Thursday, May 14, 2026, the Minneapolis Heart Institute Foundation hosted “At the Heart of Cardiovascular Disease Prevention 2026,” an evening dinner symposium at Southview Country Club in West St. Paul, MN. The event brought together nearly 100 physicians, advanced practice providers, nurses, and other healthcare professionals to focus on current guidelines, prevention strategies, and treatment options aimed at reducing the burden of cardiovascular disease.

The 2026 TMVR/TTVR Planning Workshop brought together a global community of structural heart specialists for an intensive, hands‑on CT planning experience focused on transcatheter mitral and tricuspid interventions.

During Women’s Health Month in May, the Minneapolis Heart Institute Foundation (MHIF) is proudly celebrating a special milestone moment: the successful enrollment of a patient in a clinical trial of the BrioVAD technology led by an all-female team, from the cardiac surgeon to the nurses and research staff.

Women have historically been underrepresented in clinical research, particularly in cardiovascular studies. This has created gaps in health equity and can impact outcomes on a broad scale. At Minneapolis Heart Institute Foundation (MHIF), we are committed to changing that narrative.